RxDoctor Payments Data

George In, MD

Family Medicine · Los Angeles, CANPI 1902835077

Payments from drug & device makers

$14,355in general payments, 2019–2025

Across 165 payments — averaging $87.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$6K
  • AbbVie$5K
  • Amgen$921
  • AstraZeneca$461
  • Digestive Care, Inc.$284
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$281
  • plus $968 from 15 others

What the payments were for

  • Speaking & faculty fees$9,00063%
  • Food & beverage$5,32037%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,355 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$61,554
Medicare patients
166
Services billed
834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase163$238,042
VascepaIcosapent Ethyl201$98,839
JardianceEmpagliflozin86$87,072
JanuviaSitagliptin Phosphate85$78,028
JanumetSitagliptin Phos/Metformin Hcl43$41,609
TradjentaLinagliptin45$37,535
FarxigaDapagliflozin Propanediol40$32,190
MyrbetriqMirabegron46$24,791
LinzessLinaclotide47$24,708
TrulicityDulaglutide16$24,134
ZenpepLipase/Protease/Amylase16$19,827
Memantine Hcl ErMemantine Hcl46$13,357
Icosapent Ethyl41$10,315
Atorvastatin Calcium1,044$9,898
LicartDiclofenac Epolamine11$8,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$5,282$262,751210 claims
Boehringer IngelheimJardiance, Tradjenta$22$124,608131 claims
MerckJanuvia, Janumet$14$119,637128 claims
AstraZenecaFarxiga$461$32,19040 claims
Astellas Pharma US IncMyrbetriq$21$24,79146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →